439213-22-6

Basic information

• Product Name: METHYL D-2-(4-FLUOROPHENYL)GLYCINATE HCL
• Synonyms: METHYL D-2-(4-FLUOROPHENYL)GLYCINATE HCL;Methyl D-2-(4-fluorophenyl)glycinate hydrochloride;(R)-Methyl 2-aMino-2-(4-fluorophenyl)acetate hydrochloride;Methyl (2R)-2-aMino-2-(4-fluorophenyl)acetate hydrochloride;methyl (R)-amino-(4-fluoro-phenyl)-acetate hydrochloride;R-4-Fluorophenylglycine methyl ester hydrochloride
• CAS NO: 439213-22-6
• Molecular Formula: C₉H₁₀FNO₂*ClH
• Molecular Weight: 219.64
• Mol File: 439213-22-6.mol

Chemical Properties

• Boiling Point: 278.6 °C at 760 mmHg
• Flash Point: 122.3 °C
• Appearance: /
• Vapor Pressure: 0.00325mmHg at 25°C
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: METHYL D-2-(4-FLUOROPHENYL)GLYCINATE HCL(CAS DataBase Reference)
• NIST Chemistry Reference: METHYL D-2-(4-FLUOROPHENYL)GLYCINATE HCL(439213-22-6)
• EPA Substance Registry System: METHYL D-2-(4-FLUOROPHENYL)GLYCINATE HCL(439213-22-6)

Safety Data

• Hazardous Substances Data: 439213-22-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Design and Research:
METHYL D-2-(4-FLUOROPHENYL)GLYCINATE HCL is used as a chemical intermediate for the synthesis of various pharmaceutical compounds. Its distinct chemical features contribute to the development of new drugs and therapeutic agents.
Used in Chemical Synthesis:
METHYL D-2-(4-FLUOROPHENYL)GLYCINATE HCL is used as a reagent in the synthesis of organic compounds, particularly in the production of esters and other related chemical structures.
Used in Research and Development:
METHYL D-2-(4-FLUOROPHENYL)GLYCINATE HCL is used as a research compound to study its chemical properties and potential applications in various fields, including material science and biotechnology.

InChI:InChI=1/C9H10FNO2.ClH/c1-13-9(12)8(11)6-2-4-7(10)5-3-6;/h2-5,8H,11H2,1H3;1H

Upstream product

• 67-56-1 methanol 
• 93939-74-3 (R)-2-(4-fluorophenyl)glycine 

Downstream Products

• 1146361-89-8 methyl (R)-(4-fluorophenyl)-(2,2,2-trifluoracetylamino)-acetate 
• 174770-74-2 (R)-2-amino-2-(4-fluorophenyl)ethanol 

Relevant articles and documents

((S)-3-Mercapto-2-methylpropanamido)acetic acid derivatives as metallo-β-lactamase inhibitors: Synthesis, kinetic and crystallographic studies

The emergence and global spread of metallo-β-lactamase (MBL) mediated resistance to almost all β-lactam antibacterials poses a serious threat to public health. Since no clinically useful MBL inhibitors have been reported, there is an urgent need to develop new potent broad-spectrum MBL inhibitors effective against antibacterial resistance. Herein, we synthesized a set of 2-substituted ((S)-3-mercapto-2-methylpropanamido) acetic acid derivatives, some of which displayed potent inhibition with high ligand efficiency to the clinically relevant MBL subtypes, Verona Integron-encoded MBL (VIM)-2 and New Delhi MBL (NDM)-1. Kinetic studies revealed that the inhibitors are not strong zinc chelators in solution, and they bind reversibly to VIM-2 but dissociate very slowly. Crystallographic analyses revealed that they inhibit VIM-2 via chelating the active site zinc ions and interacting with catalytically important residues. Further cell- and zebrafish-based assays revealed that the inhibitors slightly increase susceptibility of E. coli cells expressing VIM-2 to meropenem, and they have no apparent toxicity to the viability of HEK293T cells and the zebrafish embryogenesis.

SUBSTITUTED PIPERAZINO-DIHYDROTHIENOPYRIMIDINES

The invention relates to new piperidino-dihydrothienopyrimidines of formula 1, as well as pharmacologically acceptable salts thereof, wherein X is SO or SO2, but preferably SO, and wherein R1, R2, R3 and R4 may have the meanings given in claim 1, as well as pharmaceutical compositions which contain these compounds. These new piperidino-dihydrothienopyrimidines are suitable for the treatment of respiratory or gastrointestinal complaints or diseases, inflammatory diseases of the joints, skin or eyes, diseases of the peripheral or central nervous system or cancers.

Dihydrothienopyrimidines for the Treatment of Inflammatory Diseases

The invention relates to new dihydrothienopyrimidine of formula 1, as well as pharmacologically acceptable salts, diastereomers, enantiomers, racemates, hydrates or solvates thereof, wherein X is SO or SO2, but preferably SO, and wherein R1, R2 and R3 have the meanings given in the description, and which are suitable for the treatment of respiratory or gastrointestinal complaints or diseases, inflammatory diseases of the joints, skin or eyes, diseases of the peripheral or central nervous system or cancers, as well as pharmaceutical compositions which contain these compounds.